[Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Perusicová J;Perusicová J
  • Source:
    Vnitrni lekarstvi [Vnitr Lek] 2007 Oct; Vol. 53 (10), pp. 1109-13.
  • Publication Type:
    English Abstract; Journal Article; Review
  • Language:
    Czech
  • Additional Information
    • Transliterated Title:
      Inkretinová strategie lécby diabetes mellitus 2. typu--inhibitor DPP-IV sitagliptin.
    • Source:
      Publisher: Ambit Media Country of Publication: Czech Republic NLM ID: 0413602 Publication Model: Print Cited Medium: Print ISSN: 0042-773X (Print) Linking ISSN: 0042773X NLM ISO Abbreviation: Vnitr Lek Subsets: MEDLINE
    • Publication Information:
      Publication: 2010- : Brno : Ambit Media
      Original Publication: 1973-<1994> : Praha : Avicenum
    • Subject Terms:
      Diabetes Mellitus, Type 2/*drug therapy ; Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use ; Hypoglycemic Agents/*therapeutic use ; Pyrazines/*therapeutic use ; Triazoles/*therapeutic use; Animals ; Humans ; Incretins/therapeutic use ; Sitagliptin Phosphate
    • Abstract:
      Sitagliptin, distributed under the brand name of Januvia, has been the first and so far the only dipeptidyl peptidase IV (DPP-IV) inhibitor introduced in clinical practice. The results of published clinical studies clearly demonstrate its effectiveness and safety as an oral antidiabetic. Apart from increasing the insulin level, Sitagliptin reduces the level ofglucagon. The principal advantages of Sitagliptin from the clinical point of view are: a) the ability to reduce both fasting and non-fasting glycaemia and improve the HbA(1c) values, b) the fact that it does not provoke weight increase, c) the fact that the risk of hypoglycaemia is significantly lower as compared with sulfonylurea derivatives, d) good tolerability.
    • Number of References:
      23
    • Accession Number:
      0 (Dipeptidyl-Peptidase IV Inhibitors)
      0 (Hypoglycemic Agents)
      0 (Incretins)
      0 (Pyrazines)
      0 (Triazoles)
      TS63EW8X6F (Sitagliptin Phosphate)
    • Publication Date:
      Date Created: 20071213 Date Completed: 20080205 Latest Revision: 20151119
    • Publication Date:
      20231215
    • Accession Number:
      18072437